Pistoia Alliance US Conference 2015 - 1.5.2 New data - Joe Donahue

1. Data
data
everywhere
Joe
Donahue
Senior
Vice
President
BioReference
Laboratories
October
13,
2015

2. Pistoia Alliance Meeting 2
Preparing
for
this
panel…

3. Pistoia Alliance Meeting 3
Done!

4. Pistoia Alliance Meeting 4
Let
me
be
a
bit
more
thoughHul…

5. Pistoia Alliance Meeting 5
Let
me
be
a
bit
more
thoughHul…

6. Pistoia Alliance Meeting 6

7. Pistoia Alliance Meeting 7

8. Pistoia Alliance Meeting 8

9. Pistoia Alliance Meeting 9

10. Pistoia Alliance Meeting 10

12. Pistoia Alliance Meeting 12
I
learned
a
lot
about
Pharma…
• We’re
inefficient
(on
pre.y
much
everything)
• We’re
expensive
• Not
very
good
at
integra;ng
data
• Slow
to
adopt
new
technologies
• Stagnant
pipelines
• Etc…!

13. Pistoia Alliance Meeting 13
But
no-­‐one
said
we
don’t
have
data…!

14. Pistoia Alliance Meeting 14
But
no-­‐one
said
we
don’t
have
data…!

15. We’ve
had
lots
of
data
for
a
long
Mme
• Combinatorial
Libraries
• HTS
• Genome
• Laboratory
notebooks
/
e-­‐notebooks
• Images
• Health
Records
(electronic
and
otherwise)
15 ● Pistoia Alliance Meeting ● 13 October 2015

16. Why
all
the
commoMon
all
of
a
sudden?

17. PaMent
Data
17 ● Pistoia Alliance Meeting ● 13 October 2015

18. Pistoia Alliance Meeting 18

20. PaMent
Data
• It’s
helping
us
interpret
what
we
have
• Some
of
it
is
‘dirty’
• There’s
a
lot
more
of
it
from
daily
life
–
sensors
• Lab
Data
(not
as
‘dirty’)
• EHR
data
(‘standards’
challenging)
20 ● Pistoia Alliance Meeting ● 13 October 2015

21. PaMent
Data
• It’s
helping
us
interpret
what
we
have
• Some
of
it
is
‘dirty’
• There’s
a
lot
more
of
it
from
daily
life
–
sensors
• Lab
Data
(not
as
‘dirty’)
• EHR
data
(‘standards’
challenging)
• What
are
we
allowed
to
REALLY
do
with
it
(‘Consents’)?
21 ● Pistoia Alliance Meeting ● 13 October 2015

22. Decision
Support
Knowledge
Informa;on
Data
Pre-­‐Omics
TesMng
ResultsData
Informa;on
Knowledge
WisdomManagement
Decisions
Post-­‐Omics
TesMng
Lab
Provider
Lab
Provider,
Research
Hospital,
Pharma,
PaMents
WisdomManagement
and
Research
Decisions
Laboratories
/
Lab
Data
taking
on
a
new
role

23. New
Data
• Genomics
technologies
• Laboratory
Tes;ng
Data
• Imaging
• Healthcare
data
mining
• Safety
monitoring
from
social
media
• Anything
said
on
social
media
• Data
from
Pa;ent
Groups
/
Disease
Founda;ons
• Digital
medicine
• Wearable
devices
(daily
pa;ent
data)
• Microbiome

24. • No
longer
n-­‐of-­‐1
• It’s
n-­‐of-­‐many
• DNA/RNA
technologies
and
omics
(in
general)
are
going
to
be
the
bulk
of
data
for
a
while
• Even
with
all
the
sensors,
those
‘phenotypes’
s;ll
need
‘genotypes’
• Machine
learning
and
experts
will
help
with
the
data
challenges
and
contribute
knowledge
that
helps
us
‘connect
the
dots’

25. Pistoia Alliance Meeting 25

26. Discovery
I
II
III
Launch
MarkeMng
&
Sales
Life
Cycle
Management
Phase
IV
• 10
• 100
• 1000
PaMents
(thousands)
Pharma
currently
uses
very
li.le
RWPD
in
the
R&D
process.
What
they
do
use
is
highly
controlled
T
=
~20
years
$1.4
–
2.6B
Pharma-­‐owned
highly
controlled
clinical
trials
data
Real
World
PaMent
Data
(RWPD
/
RWE)

27. Discovery
I
II
III
Launch
MarkeMng
&
Sales
Life
Cycle
Management
Phase
IV
• 10
• 100
• 1000
PaMents
(thousands)
Access
to
Real
World
Pa;ent
Data
can
help
make
be.er
decisions
throughout
the
Discovery,
Development
and
Launch
phases
of
bringing
a
medicine
to
market
T
=
~20
years
$1.4
–
2.6B
Pharma-­‐owned
highly
controlled
clinical
trials
data
Clinical
prac;ce,
pa;ents,
payers
and
providers
own
rights
to
the
data
Real
World
PaMent
Data
(RWPD
/
RWE)

28. Pistoia Alliance Meeting 28

29. Pistoia Alliance Meeting 29

30. Joe Donahue
Senior Vice President
jdonahue@bioreference.com
+1-551-223-9716 (mobile)